Evaluation of Analgesic effect of intravenous lidocaine versus intravenous morphine sulfate in pain reduction in long or short bones fractures of upper and lower limbs

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2015052622423N1

Enrollment

280

Registered

2015-10-21

Start date

2015-07-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Fracture. Condition 2: farcture. Condition 3: fracture. Condition 4: Fracture. Condition 5: fracture. Condition 6: fracture. Condition 7: fracture. Fracture of forearm Fracture at wrist and hand level Other fractures of long or short bones Fracture of shoulder and upper arm Fracture of femur Fracture of lower leg, including ankle Fracture of foot, except ankle

Interventions

Intervention 1: Control group:Intra venous morphine 0.1mg/kg bolus during 2 minutes. Intervention 2: Intervention group:Intra venous Lidocaine 1.5 mg/kg bolus during 2 minutes.

Treatment - Drugs

Control group:Intra venous morphine 0.1mg/kg bolus during 2 minutes

Intervention group:Intra venous Lidocaine 1.5 mg/kg bolus during 2 minutes

Eligibility

Sex/Gender

All

Age

15 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteris : All patients 15-65 years of age with long or short upper or lower bone fracture, referring to emergency ward of Imam Khomeini and Golestan hospital in Ahwaz city. Exclusion criterias: Persons under 15 years; People over 65 years; Pregnant and lactating women; People with loss of consciousness; Hemodynamic disorder ; Traumatic patients with evidence of intra abdominal or intra pelvic hemorrhage ; mental retard patients; History of allergy to lidocaine or morphine; People treated with NA; People with underlying disease (Coronary artery disease ; Diabetes; Heart valvular disease; history of Cardiac arrhythmia; Hypertention; Cerebrovascular disease; seizure; history of liver or renal disease); history of heart drugs; history of addiction

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Pain. Timepoint: 0-5-10-15-20-25-30-minute. Method of measurement: vas score.	—

Secondary

Measure	Time frame
Blood pressure. Timepoint: 0-10-15-20-25-30 minute. Method of measurement: with manometer.;Pulse rate. Timepoint: 0-10-15-20-25-30 minute. Method of measurement: Count per minute.;Spo2. Timepoint: 0-10-15-20-25-30 minute. Method of measurement: with pulse oximetry.;Respiratory rate. Timepoint: 0-10-15-20-25-30 minute. Method of measurement: Count per minute.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHamide Shiri

Ahvaz Jundishapoor University of Medical Sciences

shiri.h.@ajums.ac.ir?tufan16671@yahoo.com+98 613332477

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026